Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director · President and CEO | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 197,746 |
Ending reported balance
After 2026-09-11 transaction · row 24
24 source rows · reconciled sequenceRow 1 · 2026-09-09 · Sale · Disposed 131 · Balance 209,198 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 2 · 2026-09-09 · Sale · Disposed 347 · Balance 208,851 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive. Row 3 · 2026-09-09 · Sale · Disposed 522 · Balance 208,329 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive. Row 4 · 2026-09-09 · Sale · Disposed 368 · Balance 207,961 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive. Row 5 · 2026-09-09 · Sale · Disposed 512 · Balance 207,449 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive. Row 6 · 2026-09-09 · Sale · Disposed 396 · Balance 207,053 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive. Row 7 · 2026-09-09 · Sale · Disposed 644 · Balance 206,409 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive. Row 8 · 2026-09-09 · Sale · Disposed 1,040 · Balance 205,369 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive. Row 9 · 2026-09-09 · Sale · Disposed 640 · Balance 204,729 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive. Row 10 · 2026-09-09 · Sale · Disposed 520 · Balance 204,209 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive. Row 11 · 2026-09-09 · Sale · Disposed 215 · Balance 203,994 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive. Row 12 · 2026-09-09 · Sale · Disposed 505 · Balance 203,489 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive. Row 13 · 2026-09-09 · Sale · Disposed 362 · Balance 203,127 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive. Row 14 · 2026-09-09 · Sale · Disposed 160 · Balance 202,967 F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive. Row 15 · 2026-09-11 · Sale · Disposed 60 · Balance 202,907 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive. Row 16 · 2026-09-11 · Sale · Disposed 106 · Balance 202,801 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive. Row 17 · 2026-09-11 · Sale · Disposed 218 · Balance 202,583 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive. Row 18 · 2026-09-11 · Sale · Disposed 160 · Balance 202,423 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive. Row 19 · 2026-09-11 · Sale · Disposed 687 · Balance 201,736 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive. Row 20 · 2026-09-11 · Sale · Disposed 368 · Balance 201,368 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive. Row 21 · 2026-09-11 · Sale · Disposed 1,202 · Balance 200,166 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive. Row 22 · 2026-09-11 · Sale · Disposed 1,539 · Balance 198,627 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive. Row 23 · 2026-09-11 · Sale · Disposed 761 · Balance 197,866 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive. Row 24 · 2026-09-11 · Sale · Disposed 120 · Balance 197,746 F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026. F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive.
F16: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive.
F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive.
F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive.
F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive.
F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive.
F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive.
F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2025 Filed Jan 27, 2025 22:12 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,584 | $335.24 | $531,020.16 |
DisclosureSEC source: 0001628280-25-002666 · wk-form4_1738015934.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,303 F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 01:51 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,363 | $243.83 | $1,551,490.29 |
DisclosureSEC source: 0000950170-24-105650 · ownership.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,887 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantMarket Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007347 · ownership.xml · derivative · entry 3 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires not disclosed F3 · derivative.exercise_price: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.exercise_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. F3 · derivative.expiration_date: Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 18,459 | $0.00 Strike: $229.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007347 · ownership.xml · derivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,459 Underlying: Common Stock · 18,459 shares Expires 2031-01-23 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 20:24 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-007347 · ownership.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,250 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 20:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantPerformance Restricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047950 · ownership.xml · derivative · entry 2 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. F2 · kind: Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. F2 · derivative.exercise_date: Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. F2 · derivative.expiration_date: Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. F2 · derivative.underlying_shares: Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. F2 · balance_after: Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level. Read SEC document |
| September 11, 2023 Filed Sep 13, 2023 20:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-047950 · ownership.xml · nonDerivative · entry 1 Sibold William John · CIK 0001518611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of September 8, 2024, September 8, 2025, September 8, 2026 and September 8, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.